JPMorgan Chase & Co. Boosts Holdings in Simulations Plus, Inc. $SLP
JPMorgan Chase & Co. significantly increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 154.7% in the third quarter, now owning 167,646 shares valued at approximately $2.53 million. This increase occurred despite Simulations Plus missing EPS estimates and reporting a negative net margin, though it slightly beat revenue forecasts. Institutional investors collectively own about 78% of the company, and Wall Street analysts currently hold a consensus "Hold" rating for the stock with an average price target of $25.00.
AI Investing Insights - Official Homepage - Intellectia AI™
This article provides news and event updates for Simulations Plus (SLP), including its stock price, recent earnings reports, and ongoing collaborations. Key developments include partnerships with pharmaceutical companies to advance AI workflows in drug development and extensions of research collaborations with the FDA and NIEHS to enhance chemical safety assessments using computational models.
Simulations Plus (NASDAQ:SLP) Downgraded by Wall Street Zen to "Hold"
Wall Street Zen has downgraded Simulations Plus (NASDAQ:SLP) from "Buy" to "Hold," reflecting a broader analyst consensus of "Hold" with an average price target of $25.00. This downgrade follows the company's financial results, which showed a miss on quarterly EPS ($0.13 vs. $0.18 expected) despite a slight revenue beat. Institutional investors maintain a significant stake, holding about 78.08% of the stock.
Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Recommendation of "Hold" from Brokerages
Simulations Plus, Inc. (NASDAQ:SLP) has received an average "Hold" recommendation from brokerages, with an average 12-month price target of $25.00. The company recently missed earnings per share estimates but slightly beat revenue forecasts, with its stock trading near $11.96. Institutional ownership is high, and several firms have recently adjusted their stakes in SLP.
Simulations Plus Inc (SLP) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for Simulations Plus Inc (SLP). It is presented on an online trading platform, Capital.com.
Simulations Plus, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into potential securities fraud involving Simulations Plus, Inc. The inquiry follows a significant stock price drop on July 15, 2025, after the company reduced its financial guidance, cited slowdowns in software and services, and recorded a $77 million impairment charge. Investors are encouraged to contact the firm to discuss their legal rights.
Simulations Plus Inc (SLP) Stock Price Quote Today & Current Price Chart
This article provides a stock price quote and current price chart for Simulations Plus Inc (SLP). It also mentions online trading with the Capital.com investment app.
Simulations Plus Inc (SLP) Stock Price Quote Today & Current Price Chart
This article provides current stock price quotes and a price chart for Simulations Plus Inc (SLP). It also promotes online trading through the Capital.com investment app.
Tudor Investment Corp ET AL Acquires New Shares in Simulations Plus, Inc. $SLP
Tudor Investment Corp ET AL has acquired a new stake of 120,101 shares, valued at approximately $1.81 million, in Simulations Plus, Inc. The technology company's stock currently holds a "Hold" rating from analysts with a consensus target price of $25.00. Simulations Plus recently reported Q3 EPS of $0.13, missing analyst estimates, on revenue of $18.42 million.
Vanguard disaggregates holdings; Simulations Plus (SLP) shows 0 shares
The Vanguard Group has filed an amendment to a Schedule 13G/A, reporting zero beneficial ownership in Simulations Plus Inc (SLP) following an internal realignment on January 12, 2026. This realignment means that certain Vanguard subsidiaries will now report their holdings separately. The filing clarifies that Vanguard itself no longer directly holds or is deemed to hold these securities.
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) announced that it will release its second quarter fiscal 2026 financial results after market close on Thursday, April 9, 2026. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss these results, with details provided for both live webcast registration and direct call access. The webcast will also be available for replay on their investor relations page.
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) will report its second-quarter fiscal 2026 financial results after the market closes on Thursday, April 9, 2026. Following the earnings release, management will host a conference call at 5:00 p.m. Eastern Time to discuss the results, with registration available for a live webcast. Simulations Plus is a global leader in model-informed and AI-accelerated drug development, providing software and consulting solutions to the biopharma industry.
Simulations Plus' Q4 Earnings & Sales Meet Estimates, Fall Y/Y
Simulations Plus (SLP) reported Q4 earnings and sales that met estimates but declined year-over-year. The company posted adjusted EPS of $0.18 and revenue of $13.7 million, both in line with analyst expectations. Despite meeting estimates, the decline in financial performance from the previous year is notable.
Simulations Plus shares drop over 12% premarket as Q3 revenue forecast misses expectations
Simulations Plus shares fell over 12% in premarket trading after the company's Q3 revenue forecast did not meet analyst expectations. The market reacted negatively to the outlook.
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) announced that it will release its second quarter fiscal year 2026 financial results after market close on Thursday, April 9, 2026. Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss these results. The company invites investment professionals and shareholders to join the live webcast or conference call.
Press Release: Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
Simulations Plus (SLP) has announced its second quarter fiscal year 2026 earnings and scheduled a conference call. The article also briefly mentions Unity Software's (U.US) fourth-quarter financial results, reporting a 35% year-over-year revenue increase to $609 million, surpassing estimates, but a quarterly loss of 66 cents per share.
Simulations Plus (SLP) to Release Earnings on Thursday
Simulations Plus (SLP) is scheduled to release its Q2 2026 earnings on Thursday, April 2nd, with analysts forecasting earnings per share of $0.27 and revenue of $21.66 million. The company's shares are currently trading near their 12-month low, with a market capitalization of approximately $232.5 million, following a previous quarter earning miss. Analyst consensus on SLP is a "Hold" rating with an average target price of $25.00, while institutional investors and hedge funds own 78.08% of the stock.
Simulations Plus (SLP) Partners with Pharma Giants to Enhance AI in Drug Development
Simulations Plus (SLP) has announced strategic collaborations with three major pharmaceutical companies to integrate AI into drug development processes, aiming to create scalable next-generation workflows. While the company demonstrates strong financial health with robust revenue growth and a strong balance sheet, it faces challenges with declining net and gross margins. The partnerships leverage Simulations Plus's key software platforms to embed AI directly into drug development, influencing product development and commercial strategies, though investors are advised to monitor the company's profitability closely.
Three big drugmakers put AI agents into drug-development workflows
Simulations Plus, Inc. has announced strategic collaboration programs with three large pharmaceutical companies to integrate AI-enabled workflows into drug development. These programs aim to deploy next-generation AI workflows at scale, defining how AI will be used in real-world environments and informing product standardization and commercial models. The collaborations will utilize Simulations Plus’ software platforms to enable natural language interaction, data processing automation, and simulation coordination.
Simulations Plus and Three Large Pharmaceutical Companies Enter Strategic Collaboration Programs for AI-Enabled Modeling
Simulations Plus has announced strategic collaborations with three major pharmaceutical companies to integrate AI into drug development workflows. These programs will utilize Simulations Plus's software platforms to enable AI agents in model-informed drug development, facilitating natural language interaction, data automation, and complex simulation coordination. The initiative aims to standardize new AI-enabled workflows and define their deployment, governance, and integration within existing systems across the broader pharmaceutical enterprise.
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling
Simulations Plus has announced strategic collaborations with three major pharmaceutical companies to advance AI-enabled modeling in drug development. These programs aim to integrate AI into existing workflows using Simulations Plus's software platforms, focusing on creating reproducible and traceable outcomes. The initiative seeks to standardize AI deployment, governance, and integration within pharmaceutical IT systems, moving beyond experimentation to practical implementation of AI in drug development.
Model driven methods empower toxicology teams at SOT, Simulations Plus announces
Simulations Plus is showcasing its model-driven methods for toxicology teams at the SOT conference. These approaches aim to improve risk prediction and accelerate drug development. The company is highlighting workflows that enhance decision-making confidence for toxicology studies.
If You Invested $1,000 in Simulations Plus Inc (SLP)
This article analyzes the historical performance of Simulations Plus Inc (SLP) stock, detailing how a $1,000 investment would have fared over 1, 5, and 10 years, and comparing its returns to the S&P 500. It also provides a comprehensive overview of Simulations Plus Inc, including its business model, software platforms, AI integration in drug development, services offered, financial structure, regulatory alignment, and corporate governance. The company is a key player in biosimulation and AI-accelerated drug development, offering both software and consulting services to the biopharmaceutical industry.
Simulations Plus (NASDAQ:SLP) Upgraded at Wall Street Zen
Wall Street Zen upgraded Simulations Plus (NASDAQ:SLP) from "hold" to "buy" on Saturday, elevating the stock despite a recent quarterly EPS miss and its shares trading near a one-year low. The company's average analyst rating is "Hold" with a consensus target price of $25.00, and institutional investors have significantly increased their stakes, now owning approximately 78% of the company.
Simulations Plus launches interactive PK PD modeling workshop with MonolixSuite at Buffalo
Simulations Plus has launched a three-day, in-person interactive workshop on pharmacokinetics and pharmacodynamics (PK/PD) modeling at the University at Buffalo. The workshop will offer hands-on training using the MonolixSuite platform, aiming to enhance researchers' and professionals' expertise in this field. This initiative reinforces the company's dedication to advanced modeling education and streamlining clinical research.
First Light Asset Management LLC Purchases 410,603 Shares of Simulations Plus, Inc. $SLP
First Light Asset Management LLC significantly increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 115% in Q3, purchasing 410,603 additional shares to own a total of 767,760 shares, valued at approximately $11.57 million. Other institutional investors like Tributary Capital and North Star also increased their holdings, bringing total institutional ownership to about 78.08%. Despite this, analysts have a mixed "Hold" rating with a consensus target of $25.00, and the company recently missed EPS estimates, trading with a negative P/E.
SLP Stock Price, Quote & Chart | SIMULATIONS PLUS INC (NASDAQ:SLP)
This article provides a detailed overview of SIMULATIONS PLUS INC (NASDAQ:SLP) stock, including its current price, key statistics, and performance. It also covers analyst forecasts, fundamental and technical ratings from ChartMill, and financial highlights. The company profile details its operations in software and consulting services for drug discovery and development.
Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Recommendation of "Hold" by Analysts
Simulations Plus, Inc. (NASDAQ:SLP) has received a consensus "Hold" rating from ten research firms, with an average one-year price target of $25.00. Institutional investors have significantly increased their stakes in the company, despite a recent 15% stock drop and an EPS miss in its latest quarterly earnings. The company specializes in modeling and simulation software for the pharmaceutical, biotech, and chemical industries.
Simulations Plus, Inc. $SLP Shares Acquired by Royce & Associates LP
Royce & Associates LP significantly increased its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 31.6%, acquiring an additional 83,758 shares. This brings their total ownership to 348,758 shares, valued at $5.256 million, representing approximately 1.73% of the company. The news comes after Simulations Plus recently reported an EPS miss but a slight revenue beat, with the stock trading near its 52-week low and analysts holding a consensus "Hold" rating.
Simulations Plus, Inc. (SLP) Competitors
This article provides a detailed comparison of Simulations Plus, Inc. (SLP) with numerous competitors in the Medical - Healthcare Information Services industry. It outlines financial metrics such as market capitalization, current trading prices, P/E ratios, and Return on Equity (ROE) for SLP and its peers, highlighting SLP's relative volatility compared to some of its rivals. The piece serves as a resource for investors to assess SLP's position within its competitive landscape.
SLP Financials: Income Statement, Balance Sheet & Cash Flow
Simulations Plus Inc (SLP) financials for fiscal year 2025 show a revenue of $79.2M, a 13.1% increase year-over-year, but the company reported a net income loss of -$64.7M and an EPS of $-3.22. Despite strong liquidity and low debt, its operating and net margins were negative, leading to a neutral Piotroski F-Score of 4/9 and mixed earnings quality. The company holds a "Strong" Financial Profile score of 73/100, indicating overall financial health, but its profitability significantly decreased in FY2025.
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
Simulations Plus is hosting a high-impact panel discussion titled “From Debate to Deployment: Responsible, Practical AI in MIDD” at the ASCPT Annual Meeting on March 5, 2026. The panel will bring together industry and regulatory leaders to discuss the responsible implementation of AI in drug development, focusing on its current impact, strategic deployment decisions, and the regulatory principles shaping AI strategies. The discussion aims to provide practical insights for scientists and stakeholders on how AI can enhance scientific judgment and improve efficiency.
SLP SEC Filings - Simulations Plus Inc 10-K, 10-Q, 8-K Forms
This page provides access to Simulations Plus (SLP) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms. It details the company's regulatory disclosures as a California corporation in the professional, scientific, and technical services sector. The platform also offers AI-powered summaries to help investors quickly identify key information from these documents.
Simulations Plus opens registration for GastroPlus PBPK Spring School targeting new modelers
Simulations Plus has initiated registration for its GastroPlus PBPK Spring School, an educational program tailored for aspiring modelers in physiologically based pharmacokinetic (PBPK) and biopharmaceutics modeling. The curriculum is designed to quickly equip participants with practical skills, transitioning foundational knowledge into real-world biopharmaceutics applications. Further details and registration links are available on the company's official website.
Simulations Plus, Inc. (SLP) Stock Analysis: A 104% Potential Upside Despite Recent Headwinds
Simulations Plus, Inc. (SLP) is a healthcare technology company focused on AI and machine learning for drug discovery, currently trading at $12.09 with a significant drop from its 52-week high but a compelling 104% upside potential according to analyst ratings. Despite recent revenue contraction and negative EPS, the company maintains positive free cash flow and a forward P/E of 11.35, suggesting an anticipated turnaround fueled by its innovative offerings. The stock is technically oversold, potentially presenting a high-risk, high-reward investment opportunity as it prioritizes reinvestment for growth.
SLP PE Ratio & Valuation, Is SLP Overvalued
Simulations Plus Inc (SLP) is currently considered undervalued based on its forward P/E ratio of 35.10, which is significantly lower than its five-year average of 68.09. Its fair price is estimated to be between $15.18 and $25.47, making its current price of $12.09 undervalued by 20.36%. However, while its P/B ratio and FCF yield show favorable comparisons to historical averages, its P/S ratio of 4.54 is substantially above the industry average, which the analysis suggests might be unsustainable given its revenue growth.
Simulations Plus, Inc. Hits New 52-Week Low at $11.16
Simulations Plus, Inc. (a microcap company in the Software Products industry) has reached a new 52-week low of $11.16, marking a 75.4% decline over the past year. The company has reported negative results for three consecutive quarters, with decreasing operating cash flow and return on capital employed, despite high institutional holdings. This performance contrasts sharply with the S&P 500's 12.95% gain during the same period.
Simulations Plus (NASDAQ: SLP) OKs equity plan share increase
Simulations Plus shareholders approved an amendment to the 2021 Equity Incentive Plan, increasing the authorized shares for issuance from 2,500,000 to 3,450,000. This approval took place at the company's 2026 Annual Meeting of Shareholders on February 12, 2026, where directors were also re-elected, and Rose, Snyder & Jacobs LLP was ratified as the auditor. The annual meeting saw participation from approximately 66% of entitled shares.
Simulations Plus, Inc. Income Statement – GETTEX:SD3
This article presents the income statement for Simulations Plus, Inc. (SD3) listed on GETTEX, highlighting key financial figures. For Q1 2026, the company reported a total revenue of €15.88 million, marking a 6.28% increase from the previous quarter, and a net income of €582.89 thousand. The financial data is shown in both annual and quarterly formats, detailing income and expenses over several periods.
EBITDA of Simulations Plus, Inc. – GETTEX:SD3
This article provides financial information, specifically EBITDA, for Simulations Plus, Inc. (SD3) on the Gettex exchange. It appears to be a financial data page from TradingView, offering an overview of the company's financial performance.
Discipline and Rules-Based Execution in SLP Response
This article provides an AI-driven stock analysis for Simulations Plus Inc. (NYSE: SLP), recommending a short bias due to weak sentiment across all time horizons. It details several trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The analysis highlights an exceptional 133.5:1 risk-reward short setup.
Simulations Plus AGM: Shareholders Approve All Proposals, Back Annual Say-on-Pay Votes
Simulations Plus shareholders approved all proposals at their annual meeting, including the election of four directors, ratification of Rose, Snyder & Jacobs LLP as auditor, and an amendment to the 2021 Equity Incentive Plan. Shareholders also voted for an annual say-on-pay frequency, overriding the board's recommendation for a three-year cadence, although this vote is non-binding. The company expects to file final voting results within four business days.
Herald Investment Management Ltd Makes New $3.02 Million Investment in Simulations Plus, Inc. $SLP
Herald Investment Management Ltd has made a new investment of $3.02 million in Simulations Plus, Inc. (NASDAQ:SLP), acquiring 200,000 shares, representing approximately 0.99% of the company. Despite this new stake and a recent stock opening at $12.29, Simulations Plus has faced analyst downgrades and missed its quarterly EPS estimate, reporting $0.13 versus an $0.18 estimate, alongside a negative net margin of -81.66%. The company currently holds a consensus "Hold" rating from analysts with a target price of $25.00.
Simulations Plus hosts AI event at ASCPT to explore practical tools
Simulations Plus will host an event at ASCPT on Thursday, March 5th, focusing on the practical applications of AI in Model-Informed Drug Development (MIDD). Titled "From Debate to Deployment: Responsible, Practical AI in MIDD," the Lunch and Learn session will explore how AI tools can be effectively utilized in drug development. Attendees are encouraged to arrive early due to limited seating.
ROSEN, A LONGSTANDING FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company issued materially misleading business information. This investigation comes after a significant stock drop on July 15, 2025, when Simulations Plus reported sales figures that missed consensus estimates. Investors who purchased SLP securities are encouraged to contact the firm to join a prospective class action.
Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Recommendation of "Hold" by Brokerages
Simulations Plus, Inc. (NASDAQ:SLP) has received a consensus "Hold" recommendation from ten brokerages, with an average 12-month price target of $25.00. The company reported Q4 EPS of $0.13, missing estimates, but revenue beat expectations at $18.42 million. Institutional investors hold approximately 78.08% of the shares, with notable increases from firms like Tributary Capital and North Star.
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
Simulations Plus, Inc. has announced the extension of two research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). These collaborations will support ongoing research into computational approaches and new approach methodologies (NAMs) for assessing food and chemical safety. The extended projects align with regulatory guidance encouraging non-animal based research, including AI-driven and in silico methods, to modernize safety evaluations.
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
Simulations Plus, Inc. has announced the extension of two research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). These collaborations focus on advancing computational approaches and new approach methodologies (NAMs) for food and chemical safety assessments, aligning with federal initiatives to use non-animal based research. The extensions highlight the continued federal interest in evaluating AI-based approaches, an area where Simulations Plus has significant expertise.
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations of misleading business information. This investigation stems from a Benzinga article reporting that Simulations Plus' third-quarter 2025 earnings and sales fell short of expectations, leading to a significant 25.75% stock drop on July 15, 2025. Investors who purchased Simulations Plus securities are encouraged to contact the firm to inquire about joining a prospective class action lawsuit.
Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 26% Pounding
Simulations Plus, Inc. (NASDAQ:SLP) recently experienced a significant 26% drop in its share price over the last month, contributing to a 60% decline over the past year. Despite a high price-to-sales (P/S) ratio of 3.7x compared to an industry average of 2.2x, the company's revenue growth has been slower than its peers. Analysts forecast an 8.5% annual revenue growth for Simulations Plus over the next three years, lower than the industry's 13% average, suggesting its elevated P/S ratio may not be justified by future prospects.
